Citations

Clear

61 citation(s) found for "Schott, J J".

Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world
Snyder, Heather M. , Tampi, Malavika P. , Aisen, Paul S., Allegri, Ricardo, Apostolova, Liana G., Atri, Alireza, Aurora, Sheena, Caramelli, Paulo, Cummings, Jeffrey, Fox, Nick C., Hardy, John, Lamb, Bruce T., Levey, Allan, Lopez, Oscar, Mummery, Catherine, Nitrini, Ricardo, Pahlke, Sarah, Petersen, Ronald C., Pike, K. Joanne, Porsteinsson, Anton P., Rabinovici, Gil D., Rafii, Michael, Raman, Rema, Sabbagh, Marwan N., Salloway, Stephen P., Scheltens, Philip, Schott, Jonathan M., Selkoe, Dennis J., Sevlever, Gustavo, Sperling, Reisa, Tansey, Malu Gamez, Dyck, Christopher van, Zetterberg, Henrik, Carrillo, Maria C., Hardy, John , Grinberg, Lea Tenenholz, Hardy, John , Aisen, Paul , Allegri, Ricardo , Apostolova, Liana G. , Atri, Alireza , Caramelli, Paulo , Crivelli, Lucía , Cummings, Jeffrey L. , Strooper, Bart De , Fox, Nick C, Grinberg, Lea T. , Lamb, Bruce T. , López, Oscar L. , Mummery, Catherine J. , Nitríni, Ricardo , Pahlke, Sarah , Petersen, Ronald C. , Porsteinsson, Anton P. , Rabinovici, Gil D. , Rafii, Michael S. , Raman, Rema, Salloway, Stephen , Scheltens, Philip , Schott, Jonathan M. , Selkoe, Dennis J. , Sevlever, Gustavo Emilio , Sperling, Reisa Anne , Tansey, Malú G. , Dyck, Christopher H. van , Zetterberg, Henrik , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | July 28, 2026 | Volume: 22 | Issue: 7 | Pages: No page available

10.1002/alz.71696 | PMID 42516031 Get It

Abstract In response to a Cochrane review (published in April 2026) on the clinical trials of monoclonal antibodies targeting beta amyloid, this perspective outlines a number of critiques. The scientists, methodologists, subject‐matter experts, and clinicians on this perspective strongly recommend that the Cochrane editorial board consider a call for editorial response, correction of press materials, or commissioned reply to this review for four overarching reasons: (1) decision to pool antibodies that do and do not clear beta amyloid, (2) decision to include studies from a time when biomarkers of Alzheimer's disease were not available, (3) analytical and methodological limitations of the approach used, (4) conflating the distinct roles and methodological processes of systematic review and guideline methodologies, (5) contextualizing the present critique within the existing evidence‐synthesis literature, and (6) mechanistic inference beyond the scope of the presented analyses. Conclusions that may not accurately reflect treatment‐specific effects could cause significant downstream clinical and psychosocial harm to those currently undergoing treatment and their family members as well as individuals considering participation in Alzheimer's clinical trials.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Soleimani‐Meigooni, David N. , Chiotis, Konstantinos, Allen, Isabel E., Rabinovici, Gil D., Joie, Renaud La , Group, Meta-Centiloid Study, Apostolova, Liana G. , Asken, Breton M., Benzinger, Th., Betthauser, Tobey J., Bluma, Marina, Bombois, Stephanie, Bourgeat, Pierrick, Bouteloup, Vincent , Braskie, Meredith N., Brendel, Matthias, Brickman, Adam M., Bryant, Natalie, Bullich, Santiago , Carrillo, Maria C., Casaletto, Kaitlin, Cash, David M., Chang, Chiung-Chih, CHANG, H L, Chao, Yishu , Collij, Lyduine E., Corrada, Maria M., Craft, Suzanne , Dickerson, Bradford C., Dubois, Bruno, Dufouil, Carole, Fajardo, Alfonso, Farrar, Gill , Fortea, Juan, Frings, Lars , Frisoni, Giovanni B., Gardner, Raquel C., Gnörich, Johannes , Gordon, Brian A., Gu, Yuna , Guan, Yihui, Guo, Tengfei, Hanseeuw, Bernard J., Hansson, Oskar, Harrison, Theresa M., Huang, Qi, Huang, ST , Iaccarino, Leonardo, Ishii, Kazunari, Ishi, Kenji, Jagust, William J., Johnson, Sterling C., Kato, Takashi, Katsumi, Yuta, Kaye, Jeffrey, Kolinger, Guilherme D., Kramer, Joel H. , Landau, Susan M., Landeau, Brigitte, Lao, Patrick J., Lee, Sangwon, Lopresti, Brian J., Lowe, Val J. , Luchsinger, José A., Mao, Xiaoxie, March, Andrew, Masters, Colin L., Meyer, Philipp T., Mezenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, Nordberg, Agneta, O’Brien, John T., O’Bryant, Sid E., Pappas, Ioannis, Peretti, Debora E., Rowe, Christopher C., Rowe, James B., Schwartz, Daniel L., Seo, Sang Won , Shekari, Mahnaz, Smith, Ruben, Snyder, Heather M. , Sokolowski, Andrzej, Sperling, Reisa A., Sun, Pan, Taggett, Jacinda Z., Touroutoglou, Alexandra , Vaillancourt, David E., Giessen, Elsmarieke van de, Vijverberg, Jort, Villemagne, Victor L. , Villeneuve, Sylvia , Wang, Wei-en, Weiner, Michael, Woodworth, Davis, Xiao, Cally , Xie, F, Yoon, Yeojun, Yun, Mijin, Severanc, A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN,, Corrada, María M. , La Joie, Renaud , Blazhenets, Ganna , Chiotis, Konstantinos , Allen, Isabel Elaine , Rabinovici, Gil D. , Asken, Breton M. , Bejanin, Alexandre , Benzinger, Tammie L.S. , Betthauser, Tobey J. , Blūma, Marina , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Brendel, Matthias , Brickman, Adam M. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chiung‐Chih , Chang, Hsin‐I , Chêne, Geneviève , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Dufouil, Carole , Fortea, Juan , Garibotto, Valentina , Gordon, Brian A. , Guan, Yihui , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Iaccarino, Leonardo , Ishii, Kazunari , Ishii, Kenji, Jagust, William J. , Johnson, Sterling C. , Katsumi, Yuta , Kaye, Jeffrey , Koeppe, Robert A. , Kolinger, Guilherme Domingues , Landau, Susan , Landeau, Brigitte , Lao, Patrick , Lee, Sangwon, Lleó, Alberto , Lopresti, Brian J. , Malpetti, Maura , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , Nordberg, Agneta , O'Brien, John Tiernan , O’Bryant, Sid E. , Pappas, Ioannis , Quenon, Lisa , Rowe, Christopher Cleon , Rowe, James B. , Rudolph, Marc D. , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Sokolowski, Andrzej, Sperling, Reisa Anne , Sun, Pan , Taggett, Jacinda , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Vemuri, Prashanthi , Villain, Nicolas , Wang, Wei‐en , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Yun, M R

Mayo Clinic

JAMA | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13116 | PMID 42441390 Get It

Importance Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting therapies. To assist with amyloid PET evaluation and to guide clinical decision-making, images can be quantified in a standardized unit called Centiloid, the interpretation of which can vary according to the method and threshold used. Objective To collect Centiloid values from available studies and determine robust positivity cutoffs using data-driven methods and correspondence with visual reads. Data Sources PubMed search (October 2024) identified studies with Centiloid values. Corresponding authors were invited to share individual participant data. Additional data were obtained through access-controlled repositories and conference outreach (July 2024-July 2025). Study Selection Studies were included if they provided Centiloids, radiotracer, age, and sex. Data Extraction and Synthesis Each study was analyzed using a unified statistical pipeline; study estimates were pooled using random-effects meta-analysis. Main Outcomes and Measures Gaussian mixture models (GMMs) were fitted to Centiloid values for each study. In studies with a bimodal distribution (per integrated completed likelihood), single cutoffs for positivity were set as mean plus 2 SDs of the lower gaussian component. Using GMMs, a double-cutoff approach defined a lower certainty range using a 90% posterior probability cutoff for assignment to the low (amyloid-negative) vs high (amyloid-positive) component. An alternative Centiloid cutoff was derived from maximizing the correspondence (Cohen κ) with the binary visual reads when available. Results This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). The data-driven GMM approach identified a bimodal distribution in 51 studies (n = 48 786), resulting in a single cutoff for positivity of 18 Centiloids (95% CI,16-19; I 2 = 97%). The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I 2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I 2 = 95%). In analyses of correspondence with binary (positive or negative) visual reads of amyloid PET scans (n = 35 045; 36 studies), Centiloids were highly predictive of visual positivity (Cohen κ, 0.86; 95% CI, 0.83-0.89; I 2 = 96%) with a cutoff of 27 Centiloids (95% CI, 24-30; I 2 = 80%). Conclusions and Relevance In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.
Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action
Graff‐Radford, Jonathan, Boon, Baayla D. C., Westman, Eric, Groot, Colin, Jones, David T., Grinberg, Lea T., Rabinovici, Gil D., Whitwell, J R, Apostolova, L G, Mj, Murray, Hammers, Dustin B., Schindler, Suzanne E., Atonsdottir, Inga, Schott, J J, Illán‐Gala, Ignacio, Chukwuanugo, Ogbuagu, Guerra, Jorge J. Llibre, Peters, Ruth, Abner, Erin L., Abdelnour, Carla , A, Cortes Llado, Joie, Renaud La, Souza, Leonardo Cruz de, Shir, Dror , Pijenburg, Yolande A. L., Carrillo, Maria C., Dickerson, Bradford C, Aisen, P, Ossenkoppele, Rik, Raman, Rema, Joie, Renaud La , Corriveau-Lecavalier, Nick , La Joie, Renaud , Shir, Dror , Corriveau‐Lecavalier, Nick , Falgàs, Neus , Putcha, Deepti , Graff‐Radford, Jonathan , Yong, Keir , Boon, Baayla D.C. , Mohanty, Rosaleena , Westman, Eric , Groot, Colin , Jones, David T. , Grinberg, Lea T. , Rabinovici, Gil D. , Whitwell, Jennifer L. , Apostolova, Liana G. , Hammers, Dustin B , Schindler, Suzanne E. , Rhodus, Elizabeth K. , Illán‐Gala, Ignacio , OGBUAGU, CHUKWUANUGO, Abner, Erin L. , Souza, Leonardo Cruz de , Rezaii, Neguine , Carrillo, María C. , Dickerson, Bradford Clark , Aisen, Paul , Ossenkoppele, Rik , Raman, Rema

Mayo Clinic

Alzheimer's & Dementia | June 23, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71521 | PMID 42334062 Get It

Abstract Patients with atypical variants of Alzheimer's disease (AD) often present at a younger age with predominantly non‐amnestic impairments and a more aggressive disease course. Historically, individuals with atypical presentations have not been included in large‐scale clinical trials, which typically focus on late‐onset, sporadic amnestic‐predominant AD. Consequently, treatment options and research efforts specific to atypical AD remain limited. The emergence of amyloid‐targeting therapies that slow disease progression underscores these challenges, as evidence supporting their efficacy in early‐onset amnestic and non‐amnestic AD variants is scarce. This perspective article argues that atypical AD represents an excellent disease model for clinical trials and proposes strategies to address critical gaps in clinical trial design for this population. Key considerations include optimizing participant selection approaches, establishing syndrome‐specific or surrogate biological and clinical endpoints, and fostering advocacy to enhance early and accurate diagnosis, equitable representation, and outcomes for these populations.
Ventricular conduction is a marker for arrhythmic risk in SCN5A- E1784K overlap sodium channel disease
Tanck, Michael W.T. , Wijeyeratne, Yanushi D. , Barc, Julien , Muir, A.J.L., Aiba, Takeshi , Bos, Martijn, Veltmann, Christian , Galvin, Joseph , Crotti, Lia , Ishikawa, Taisuke , Ohno, Seiko , Page, Stephen P, Denjoy, I, Tester, David J. , Muggenthaler, Martina, Takahashi, Kazuhiro , GOURRAUD, JEAN BAPTISTE, Haglund-Turnquist, Carla, Pedrazzini, Matteo , Alberio, Chiara , Petzer, Edward, Roden, Dan M. , Borggrefe, Martin , Ackerman, Michael J. , McKeown, Pascal , Behr, Elijah R. , Bos, J. Martijn , Bos, Johan M , Denjoy, Isabelle , Raju, Hariharan , Gourraud, Jean-Baptiste , Redon, Richard , Jacques Schott, Jean , Pedrazzini, Matteo , Alberio, Chiara , Dagradi, Federica , Papadakis, Michael , Sharma, Sanjay , Petzer, Edward , Roden, Dan M. , Horie, Minoru , Schwartz, Peter J. , Makita, Naomasa , Borggrefe, Martin , Shimizu, Wataru , Probst, Vincent , Behr, Elijah Raphael , Ishikawa, Taisuke , Crotti, Lia , Tanck, Michael , Barc, Julien , Aiba, Takeshi , Veltmann, Christian , Galvin, Joseph , Ohno, Seiko , Denjoy, Isabelle , Muggenthaler, Martina, Gourraud, Jean‐Baptiste , Redon, Richard , Schott, Jean‐Jacques , Haglund-Turnquist, Carla , Dagradi, Federica

Mayo Clinic

Europace | May 9, 2026 | Volume: 28 | Issue: 6 | Pages: No page available

10.1093/europace/euag113 | PMID 42114100 Get It

Abstract Aims SCN5A-E1784K (c.5350G>A) is the most common variant associated with the long QT (LQTS) and Brugada syndromes (BrS). It can manifest variably as LQTS, BrS, and/or conduction disorders. This presents a challenge for risk stratification. We aimed to describe clinical and ECG characteristics and identify risk markers that associate with arrhythmic events. Methods and results We undertook a retrospective observational multicentre study of a large cohort of 231 subjects with SCN5A-E1784K from Europe, USA, and Japan. Comprehensive demographic and clinical data, including initial presentation ECG and follow-up, were collected. ‘Lethal events’ were defined as sudden death, non-fatal cardiac arrest, and documented sustained VT or VF. ‘Cardiac events’ were defined as arrhythmic syncope plus any lethal events. Clinical characteristics and ECG parameters corrected for age were investigated for association with lethal and/or cardiac events. Fourteen (6%) subjects experienced a lethal event and 45 (19%) a cardiac event. PR interval and QRS duration were associated with lethal and cardiac events. In multivariable models, both PR interval and QRS duration were associated with lethal events, but only QRS duration was associated with cardiac events. Only age-corrected QRS (rQRS) was associated with lethal and cardiac event-free survival from birth after correction for multiple testing. Conclusion Ventricular myocardial conduction appears likely to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. This provides an important opportunity for the personalization of management and has the potential to guide preventative therapies.
Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve
Thériault, Sébastien , Holdcraft, Jacob A., Sharipova, Dinara , Dębiec, Radosław , Peloso, Gina M., Al‐Kassou, Baravan , Swan, Elena Ashikhmina , Ballotta, Andrea, Björck, Hanna M. , Braund, Peter S. , Corriveau, François, Dagenais, François, Francke, Michael, Gorbatov, Svetlana, Guo, Dongchuan, Habchi, Karam M, Scouarnec, Solena Le , Lichtner, Peter , Nguyen, Thy B., Norris, R., Pibarot, P, Simonet, Floriane, Tm, Sundt, Tessler, Idit , Willer, Cristen J., Wittmann, Susanne, Yang, Bo, Berezovets, Igor, Doppler, S. , Dreßen, Martina, Knoll, Katharina, Puehler, T., Schunkert, H, Bissell, Malenka M. , Bolger, Aidan, Brion, M, Citro, Rodolfo, Deeb, G. Michael, Corte, Alessandro Della, Dina, C., Eriksson, Per, Evangelista, Arturo , Franco-Cereceda, Anders, Gilon, Dan, Hetherington, Simon, Huggins, G S, Krane, Markus , Tourneau, Thierry Le, Limongelli, Giuseppe, Mathieu, P., Messika-Zeitoun, David, Michelena, Hector I., Milewicz, Dianna, Murdock, David R. , Nickenig, G., Nistri, Stefano, Nöthen, M, Samani, Nilesh J. , Schott, J., Webb, Tom R., Abdelilah-Seyfried, Salim, Schumacher, Johannes, Trenkwalder, Teresa , Body, Simon C. , Dina, Christian , Brión, Marı́a , Peloso, Gina M. , Webb, Tom R. , Faucherre, Adèle , Debiec, Radoslaw M , Peloso, Gina M , Al-Kassou, Baravan , Aranki, Sary , Ashikhmina Swan, Elena , Björck, Hanna M , Boureau, Anne Sophie , Braund, Peter S , Folkersen, Lasse , Guo, Dongchuan , Heydarpour, Mahyar , Isselbacher, Eric M , Jopling, Chris , Laporte, Fabien , Le Scouarnec, Solena , Li, Zhonglin , Lichtner, Peter , Maj, Carlo , Manikpurage, Hasanga D , Nguyen, Thy B , Norris, Russell A , Pibarot, Phillippe , Sarubbi, Berardo , Simonet, Floriane , Sundt, Thoralf , Surakka, Ida , Tessler, Idit , Yang, Bo , Doppler, Stefanie A , Dreßen, Martina , Knoll, Katharina , Puehler, Thomas , Schunkert, Heribert , Bissell, Malenka M , Bossé, Yohan , Bossone, Eduardo , Brion, María , Citro, Rodolfo , de Vincentiis, Carlo , Deeb, G Michael , Della Corte, Alessandro , Dina, Christian , Durst, Ronen , Ensminger, Stephan , Eriksson, Per , Evangelista, Arturo , Franco-Cereceda, Anders , Gilon, Dan , Giusti, Betti , Hetherington, Simon L , Huggins, Gordon S , Le Tourneau, Thierry , Limongelli, Giuseppe , Mathieu, Patrick , Messika-Zeitoun, David , Michelena, Hector I , Milewicz, Dianna M , Muehlschlegel, Jochen D , Murdock, David R , Nickenig, Georg , Nistri, Stefano , Nöthen, Markus M , Prakash, Siddharth K , Samani, Nilesh J , Jacques Schott, Jean , Webb, Tom R , Zaffran, Stéphane , Eagle, Kim , Body, Simon C , Holdcraft, Jacob A., Bellino, Michele , Dagenais, François, Forte, Amalia , Frigiola, Alessandro , Guo, Dongchuan , Isselbacher, Eric M. , Nelson, Christopher P. , Ong, Chin Siang , Roychowdhury, Tanmoy , Surakka, Ida , Willer, Cristen J , Aviérinos, Jean-François , Bolger, Aidan P. , Bossé, Yohan , Bossone, Eduardo , Citro, Rodolfo , Deeb, G. Michael , Corte, Alessandro Della , Gilon, Dan, Huggins, Gordon S. , Tourneau, Thierry Le , Mathieu, Patrick , Messika–Zeitoun, David , Nistri, Stefano , Nöthen, Markus M. , Pluchinotta, Francesca Romana , Prakash, Siddharth K. , Schott, Jean‐Jacques , Zaffran, Stéphane , Abdelilah‐Seyfried, Salim , Eagle, Kim A. , Schumacher, Johannes

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 14 | Pages: 1060-1076

10.1161/circulationaha.125.074752 | PMID 41645906 Get It

BACKGROUND: Bicuspid aortic valve (BAV) is a frequent congenital heart defect with a high heritability. Despite this, only a limited number of genes have been associated with the disease, and the molecular mechanisms remain unexplained in most cases. This study aimed to further understand the genetic architecture of BAV. METHODS: A genome-wide association study meta-analysis including 9631 cases among 65 677 participants was performed. Genes were prioritized using transcriptomic analyses based on RNA sequencing in relevant tissues, including human fetal and adult aortic valves. The impact of the knockdown or knockout of 4 candidate genes on cardiac development was verified in zebrafish. A polygenic risk score was developed, its association with BAV was evaluated in an independent cohort, and its association with a wide range of phenotypes (n=976) was evaluated in UK Biobank (n=355 618 individuals). RESULTS: Thirty-six genomic loci were identified, including 32 that were not described previously. Among the prioritized genes, KANK2 and ERBB4 were identified as potentially causal through transcriptomic analyses, colocalization, and Mendelian randomization based on gene expression in human aortic valves (n=484), whereas PRDM6 and STRN were prioritized using similar analyses from aortic (n=326) and left ventricular tissues (n=326), respectively. Targeting 4 candidate genes ( WNT4 , LEF1 , STRN , and KANK2 ) in zebrafish led to disruption in cardiac development. A polygenic risk score was associated with an odds ratio of 2.07 (95% CI, 1.90–2.25; P =5.43×10 -62 ) per SD for BAV and significantly associated with thoracic aortic aneurysm and atrial fibrillation in UK Biobank. CONCLUSIONS: This study supports a significant polygenic contribution to BAV, where the combination of multiple common variants in genes involved in heart morphogenesis disrupts aortic valve development.
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Asken, Breton M., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N., Carrillo, Maria C., Casaletto, Kaitlin B, Cash, David M, Chang, Hsin‐I., Chao, Yishu , Chételat, Gael, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hanseeuw, Bernard J, Hansson, Oskar H., Harrison, Theresa, Huang, Qi, Huang, Shu‐Hua , Ishii, K, Ishii, Kenji, Jagust, William J., Katou, Rikio, Koeppe, Robert A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J, Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis, Rowe, Christopher C., Salvadó, Gemma, Schott, Jonathan M, Schwartz, Daniel, Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz , Silbert, Lisa C, Smith, Ruben, Sokolowski, Andrzej, Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, D., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Vemuri, Prashanthi, Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Joie, Renaud La, Consortia, AMYPAD and LEADS, Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chia‐Hsuin , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kenji, Jagust, William J. , Koeppe, Robert A. , Kramer, Joel H. , Landau, Susan , Landeau, Brigitte , Lee, Sangwon, Lopresti, Brian J. , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , O’Bryant, Sid E. , Pappas, Ioannis , Peretti, Débora Elisa , Quenon, Lisa , Rowe, Christopher C., Salvadó, Gemma , Schott, Jonathan M. , Schwartz, Daniel L., Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villain, Nicolas , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107124 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen's kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure 1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure 1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure 2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure 2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.
Sex, education and race/ethnicity have distinct effects on amyloid and tau‐PET status
Groot, Colin , Rowe, Christopher C., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Pijnenburg, Yolande A.L., Visser, Pieter Jelle, Braber, Anouk den, Pontecorvo, Michael J. , Burnham, Samantha C., Lu, Ming , Jagust, William J., Baker, Suzanne L. , Harrison, Theresa, Gispert, Juan Domingo, Shekari, Mahnaz , Minguillón, Carolina, Smith, Ruben, Mattsson‐Carlgren, Niklas, Palmqvist, Sebastian, Strandberg, Olof, Stomrud, Erik, Brickman, Adam, Manly, Jennifer J., Lao, Patrick J., Kreisl, William Charles, Malpetti, Maura, O'Brien, John T, Jäger, Elena, Bischof, Gérard, Drzezga, Alexander, Xie, Fang, Mao, Xiaoxie, Guan, Yihui, Frisoni, Giovanni B, Peretti, Débora Elisa , Skoog, I., Kern, Silke, Sperling, Reisa A., Johnson, Keith A., Risacher, Shannon, Saykin, Andrew J., Carrillo, Maria C., Dickerson, Brad C., Apostolova, Liana G., Rabinovici, Gil D., Barthel, H, Messerschmidt, Konstantin, Vandenberghe, Rik, Laere, Koen J. Van, Spruyt, Laure , Petersen, Ronald, Jack, Clifford R., Franzmeier, Nicolai, Brendel, Matthias, Gnörich, Johannes, Benzinger, Tammie L.S., Lagarde, Julien, Sarazin, Marie , Villeneuve, Sylvia , Poirier, Judes, Seo, Sang Won, Gu, Yuna , Kim, Jun Pyo, Mormino, Beth C., Vossler, Hillary , Rosa‐Neto, Pedro, Therriault, Joseph, Rahmouni, Nesrine, Cash, David M, Schott, Jonathan M, Hanseeuw, Bernard J, Jansen, Willemijn J. , Joie, Renaud La, Rosen, Howard J., Johnson, Sterling C., Christian, Bradley T, Betthauser, Tobey J., Landau, Susan M., O'Bryant, Sid E., Hansson, Oskar H., Ossenkoppele, Rik, Prevent‐AD, ADNI, ADNI‐DOD, A‐Study, MCSA,, O’Brien, John T. , O'Brien, John Tiernan , Groot, Colin , Coomans, Emma M. , Rowe, Christopher C., Doré, Vincent , Feizpour, Azadeh , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Pijnenburg, Yolande A.L. , Visser, Pieter Jelle , Braber, Anouk den , Burnham, Samantha C. , Kennedy, Ian Andrew , Jagust, William J. , Harrison, Theresa M. , Gispert, Juan Domingo , Shekari, Mahnaz , Minguillón, Carolina , Smith, Ruben, Mattsson, Niklas , Palmqvist, Sebastian , Strandberg, Olof, Stomrud, Erik , Brickman, Adam M. , Luchsinger, Jose Alejandro , Manly, Jennifer J. , Lao, Patrick , Malpetti, Maura , Rowe, James B. , Bischof, Gérard N. , Drzezga, Alexander E. , Xie, Fang , Guan, Yihui , Garibotto, Valentina , Frisoni, Giovanni B. , Schöll, Michael , Kern, Silke , Sperling, Reisa Anne , Johnson, Keith A. , Risacher, Shannon L. , Saykin, Andrew J. , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Rabinovici, Gil D. , Rullmann, Michael , Messerschmidt, Konstantin, Vandenberghe, Rik , Petersen, Ronald, Jack, Clifford R. , Franzmeier, Nicolai , Brendel, Matthias , Gnörich, Johannes , Benzinger, Tammie L.S. , Lagarde, Julien , Bottlaender, Michel , Poirier, Judes , Seo, Sang Won , Kim, Jun Pyo, Young, Christina B. , Rosa-Neto, Pedro , Therriault, Joseph , Rahmouni, Nesrine , Coath, William , Cash, David M. , Schott, Jonathan M. , Hanseeuw, Bernard , Salman, Yasmine , Malotaux, Vincent , Joie, Renaud La , Rosen, Howard J. , Johnson, Sterling C. , Christian, Bradley T. , Betthauser, Tobey J. , Landau, Susan , O’Bryant, Sid E. , Hansson, Oskar , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105387 Get It

Abstract Background Sex, education and race/ethnicity are all associated with risk of Alzheimer's disease dementia. Here, we assess the effects of self‐reported sex, educational attainment and race/ethnicity on amyloid‐positivity, and tau‐PET‐positivity in 12,048 (7,394 cognitively unimpaired [CU], 2,177 MCI, and 2,477 dementia) individuals from 42 cohorts worldwide. Method Logistic generalized estimating equations were used to estimate frequency of amyloid‐positivity (using cohort‐specific thresholds for amyloid‐PET [84%] or CSF) and tau‐PET‐positivity (cohort‐specific thresholds of 2SD above mean temporal uptake in amyloid‐negative controls). We assessed: i) sex and APOEε4 ( N = 10,098) associations, to complement earlier findings of a higher frequency of tau‐positivity in females, ii) effects of lower/higher education ( N = 10,970; cohort‐specific median‐split), and iii) effects of race/ethnicity (non‐Hispanic White [hereafter: White], N = 4880; Asian, N = 116; Black or African‐American [hereafter: Black], N = 353; Hispanic, N = 356, only from Northern‐American cohorts). Outcomes were frequency of amyloid‐positivity in CU individuals only, and tau‐PET‐positivity in both amyloid‐positive (AB+) CU and cognitively impaired (CI, i.e. MCI and dementia) individuals. Interaction effects on the relationship between age and amyloid/tau‐positivity were assessed and only retained in the models when significant. Result Female sex was associated with an APOEε4 ‐independent increased frequency of amyloid‐positivity (β=0.51[0.22], p = 0.02) in CU and increase of tau‐positivity in both AB+CU (β=0.27[0.08]) and AB+CI (β=0.37[0.08], both p <0.01). Remarkably, tau‐positivity frequencies of female APOEε4 non‐carriers were equivalent to male APOEε4 carriers in AB+CI (Figure 1). No significant sex* APOE interactions were observed. In CU, higher education was associated with lower amyloid‐positivity frequency (β=‐0.12[0.05], p = 0.02). In contrast, among AB+CU, there was an age*education interaction effect that indicated more pronounced age effects on tau‐positivity in individuals with higher education (age*education:β interaction =0.03[0.01], p <0.01). There were no education effects in AB+CI (Figure 2). In CU, an age*race/ethnicity interaction effect was observed across all non‐White groups compared to White (Hispanic:β interaction =‐0.05[0.01], p <0.01; Black:‐0.04[0.01], p <0.01; Asian:‐0.02[0.01], p = 0.04). This suggests that the impact of age on amyloid‐positivity was less pronounced in non‐White groups. Furthermore, in AB+CI, Hispanic ethnicity was related to higher tau‐positivity frequency than White (β=0.51[0.22], p = 0.02; Figure 3). Conclusion In this multi‐center initiative comprised of clinical and community‐based cohorts, we observed that self‐reported sex, educational attainment and race/ethnicity were related to positivity‐frequencies of Alzheimer's disease pathology.
Heterogeneous tau patterns in atypical AD are explained by connectivity‐associated tau progression
Bruin, Hannah de , Groot, Colin , (ADNI), Alzheimer's Disease Neuroimaging Initiative, Barthel, Henryk, Bischof, Gérard N. , Boon, Baayla D.C., Brendel, Matthias, Cash, David M, Day, Gregory S, Dickerson, Brad C., Dyck, Christopher H van, Flier, Wiesje M. van der, Fredericks, Carolyn , Fryer, Tim D. , Giessen, Elsmarieke van de, Gordon, Brian A., Radford, Jonathan Graff, Hansson, Oskar H., Höglinger, Günter U, Hönig, Merle C., Irwin, David J., Jones, P Simon, Josephs, Keith A., Katsumi, Yuta , Lee, Eddie B., Xiong, Chengjie , McGinnis, Scott M., Mecca, Adam P. , O'Brien, John T, O'Dell, Ryan S, Rabinovici, Gil D., Rahmouni, Nesrine, Rosa‐Neto, Pedro, Sabri, Osama, Schott, Jonathan M, Schroeter, Matthias L, Seeley, William W., Servaes, Stijn, Sintini, Irene , Smith, Ruben, Stevenson, Jenna , Strandberg, Olof, Therriault, Joseph, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip SJ., Whitwell, Jennifer L., Yong, Keir X X, O’Brien, John T. , Rabinovici, Gil D. , Day, Gregory S. , O'Brien, John Tiernan , Day, Gregory S , Xiong, Chengjie , Rabinovici, Gil D , Groot, Colin , Initiative, Alzheimer's Disease Neuroimaging, Blazhenets, Ganna , Boellaard, Ronald , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Dickerson, Brad C., Doering, Elena , Drzezga, Alexander E. , Dyck, Christopher H. van , Eimeren, Thilo van , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Hobbs, Diana A. , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Josephs, Keith A. , Joie, Renaud La , Lee, Eddie B, Malpetti, Maura , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Palleis, Carla , Perneczky, Robert , Phillips, Jeffrey S , Putcha, Deepti , Rahmouni, Nesrine , Rosa-Neto, Pedro , Rowe, James B. , Rullmann, Michael , Saur, Dorothee , Schildan, Andreas , Schott, Jonathan M. , Schroeter, Matthias L , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Stomrud, Erik , Therriault, Joseph , Visser, Denise , Weston, Philip S.J. , Whitwell, Jennifer L. , Wolk, David A. , Yong, Keir , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 7, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_104871 Get It

Abstract Background The link between regional tau load and clinical manifestation of Alzheimer's disease (AD) highlights the importance of characterizing spatial tau distribution. In typical (memory‐predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicenters. However, atypical (non‐amnestic‐predominant) AD variants with heterogeneous tau patterns provide a key opportunity to assess the universality of connectivity as a scaffold for tau progression. Method We included tau‐PET data from 320 subjects with atypical AD, characterized by highly heterogeneous tau patterns ( n = 139 posterior cortical atrophy/PCA‐AD; n = 103 logopenic variant primary progressive aphasia/lvPPA‐AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS‐AD) from 14 sites, with a subset of patients ( n = 78) having longitudinal tau‐PET data. As an independent sample, we further included regional post‐mortem tau stainings from 93 atypical AD patients from two sites ( n = 19 PCA‐AD, n = 32 lvPPA‐AD, n = 23 bvAD, n = 19 CBS‐AD). Gaussian mixture modeling was used to harmonize different tau‐PET tracers by transforming tau‐PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether 1) brain regions with stronger functional connectivity showed greater covariance in cross‐sectional and longitudinal tau‐PET and post‐mortem tau pathology, and 2) functional connectivity of tau‐PET epicenters and tau‐PET accumulation epicenters was associated with cross‐sectional and longitudinal tau patterns. Result Tau‐PET epicenters—defined as the 5% brain regions with the highest tau load—aligned with clinical variants, e.g. a posterior pattern in PCA‐AD (“visual AD”) and left‐hemispheric temporal predominance in lvPPA‐AD (“language AD”) (Figure 1). More strongly functionally connected regions showed correlated concurrent tau‐PET levels, which was confirmed with post‐mortem data (Figure 2). Moreover, the connectivity profile of tau‐PET epicenters and accumulation epicenters corresponded to tau‐PET progression patterns (Figure 3). Conclusion Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicenters, across all AD clinical variants. Since tau proteinopathy is a key driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant‐specific endpoints in clinical trials.
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N. , Carrillo, Maria, Casaletto, Kaitlin B, Chang, C. -C., Chang, Hsin‐I., Chao, Yishu , Chetelat, Gaël, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hansson, Oskar H., Huang, Q., Huang, Shu‐Hua , Ishii, Kenji, Jagust, William J., Kato, Takashi , Koeppe, R. A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J. , Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C. , Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis G., Rowe, C. C., Schott, Jonathan M, Schwartz, Daniel L. , Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz, Smith, Ruben, Sokołowski, Andrzej , Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, David E. , Flier, Wiesje M. van der, Vemuri, Prashanthi, Villain, Nicolas , Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Wang, Wei‐en , Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Casaletto, Kaitlin B. , Cash, David M. , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Brad C., Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kazunari , Jagust, William J. , Kramer, Joel H. , Landau, Susan, Landeau, Brigitte , Masters, Colin L. , Mézenge, Florence, Nakamura, Akinori , O’Bryant, Sid E. , Peretti, Débora Elisa , Quenon, Lisa , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Sokolowski, Andrzej, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110011 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen’s kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure‐1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure‐1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure‐2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure‐2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.
Navigating the Risks Beyond the Label: Unpacking Global Nutritional Supplement Safety
Wardenaar, Floris C. , Burns, Stephen F. , Campos, Marcus Vinícius Simões de , Chan, Yat C. , Claassen-Smithers, Amanda , Dunshea-Mooij, Christel A.E. , Haddou, Salah Eddine, Hoogervorst, Daan , García, P. , Garthe, Ina, Nugent, Anne P. , Aly, Maged Ossama , Schott, Kinta D. , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Campos, Marcus , Chan, Yat , Dunshea-Mooij, Christel , Jagim, Andrew R , Garcia, Pedro Reinaldo , Nugent, Anne P , Aly, Maged Ossama , Saunders, Bryan , Schott, Kinta D , Sekiguchi, Yasuki , Slater, Gary , Speers, Naomi , Stratton, Matthew T , Aussieker, Thorben , Jagim, Andrew R. , Stratton, Matthew T.

Mayo Clinic

International Journal of Sport Nutrition and Exercise Metabolism | December 17, 2025 | Volume: 36 | Issue: 2 | Pages: 134-166

10.1123/ijsnem.2025-0177 | PMID 41468235 Get It

Nutritional supplement use is common among athletes aiming to enhance performance, recovery, and health. However, variable regulatory frameworks and limited safety oversight create risks for inadvertent doping violations. This article provides a global overview of supplement use, relevant authorities, legislation, and safety measures, with a focus on third-party testing (TPT) as a risk-mitigation strategy. Data from six global regions—Africa, Asia, Australia/New Zealand, Europe, Latin America, and North America—were synthesized from peer-reviewed studies, governmental sources, and regional expert contributions. Reported supplement use ranged from 7% to 100% among athletes (variability within regions), with protein powders, vitamins/minerals, creatine, caffeine, and sports drinks being most prevalent. High-risk products (potential anti-doping rule violations), including certain herbal blends, preworkouts, and weight-management supplements, were reported across all regions. While some countries have robust regulatory systems, most lack harmonized or enforceable safety frameworks. TPT programs, which independently verify products for prohibited substances, remain concentrated in the global northwest (Europe, North America, and Australia/New Zealand); awareness and use of TPT certification vary widely, and even in regions with established systems, athlete adherence is inconsistent. Barriers to low-risk supplement use are limited TPT availability, cost, differences in labeling (including language), and cultural factors. Firsthand experiences and perceptions highlight widespread misconceptions about supplement safety and certification. The authors recommend expanded athlete and team-around-the-athlete education, improved global access to TPT low-risk supplements, and policy initiatives to harmonize safety standards. This work emphasizes the need for coordinated international efforts to protect athlete health and integrity while allowing access to evidence-based supplementation.